# OnCo record paper-cunningham-trak-er-surveillance-ann-oncol-2026 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-cunningham-trak-er-surveillance-ann-oncol-2026/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-cunningham-trak-er-surveillance-ann-oncol-2026" ;
  schema:name "Prospective circulating tumour DNA surveillance in patients with early high-risk hormone receptor positive, HER2-negative breast cancer in the TRAK-ER study"@en ;
  schema:description "In TRAK-ER, three-monthly blood tests found tumour DNA in about one in eight women with high-risk hormone-receptor-positive breast cancer, but two thirds of those found on their first test already had cancer visible on scans."@en ;
  schema:url <https://onco.cc/key-papers/paper-cunningham-trak-er-surveillance-ann-oncol-2026/> ;
  schema:dateModified "2026-11-04"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/j.annonc.2026.10.1292>, <https://pubmed.ncbi.nlm.nih.gov/42946309/> ;
  schema:sameAs <https://doi.org/10.1016/j.annonc.2026.10.1292> ;
  schema:datePublished "2026"^^xsd:gYear ;
  schema:author "Cunningham N, Swift C, Cutts RJ, et al." ;
  onco:cancers <https://onco.cc/cancers/breast-hr-positive/> ;
  onco:sections <https://onco.cc/fronts/diagnostics/> ;
  onco:technologies <https://onco.cc/technologies/mrd-testing/> ;
  onco:drugs <https://onco.cc/drugs/palbociclib/>, <https://onco.cc/drugs/fulvestrant/> ;
  onco:companies <https://onco.cc/companies/labcorp/> ;
  onco:terms <https://onco.cc/terms/mrd/>, <https://onco.cc/terms/ctdna/>, <https://onco.cc/terms/tumour-informed-assay/> ;
  onco:trials <https://onco.cc/trials/trak-er/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-subclone-attribution-residual-disease/> ;
  onco:journals <https://onco.cc/journals/annals-of-oncology/> .